Radiopharmaceutical · Kills target cells, directed at somatostatin receptor 2 (SSTR2) · developed by Molecular Targeting Technologies
Lutetium Lu 177-DOTA-EB-TATE is a radioconjugate of a tyrosine-containing somatostatin analog (Tyr3-octreotate) linked to a DOTA chelator carrying the beta-emitting isotope lutetium-177, with an Evans blue moiety that binds albumin. It binds somatostatin receptor 2 on neuroendocrine tumor cells, is internalized, and delivers beta radiation to those cells. It is studied in neuroendocrine tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05475210 | Phase 1 | Neuroendocrine Tumors | Completed | MOLN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Neuroendocrine Tumors
Updated Nov 15, 2026. Something wrong or missing? Report it on the MOLN page.
See MOLN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MOLN catalysts and pipeline →